A relaxed fundus (FUN) and a contracted lower uterine segment (LUS) of human myometrium are required for maintaining pregnancy. How this regional myometrium function is regulated remains unclear. We have previously reported that the homeobox protein A13 (HoxA13) is highly expressed in the LUS and can enhance the expression of contraction-associated proteins (CAPs). Here, we show that in contrast to HoxA13, HoxA10 and HoxA11 genes are expressed at significantly higher levels in myometrium tissues and primary myocytes from the FUN. When introduced exogenously into a human myometrial cell line, HoxA10 and HoxA11 suppress the messenger RNA (mRNA) levels of several CAP genes including interleukin-1 beta (IL-1b), IL-6, connexin 43 (Cx43), and cyclooxygenase 2 (Cox2). Consistently, enhanced HoxA10 and HoxA11 expressions strongly inhibited IL-1b and Cx43 protein levels. We further confirmed that higher expression of HoxA10 and HoxA11 genes in primary myocytes from the FUN compared to that from the LUS was associated with lower expression of IL-1b, IL-6, Cox2, and Cx43 genes. We conclude that the expression patterns of HoxA10, HoxA11, and HoxA13 and their actions in regulating CAP genes in FUN and LUS create regionalized myometrium phenotypes in women that may be important to control regionalized myometrium contractility for maintaining pregnancy.
Introduction
Although preterm birth affects 1 in every 11 pregnancies, it is associated with 70% of neonatal mortality and up to 75% of neonatal morbidity (http://www.cdc.gov/features/premature birth). Even when infants survive, they often face lifetime disability or require costly medical care. To effectively prevent preterm birth and identify potential therapeutic targets, we need to understand how the myometrium is maintained in a relatively quiescent state during pregnancy and how the myometrium contraction is initiated at the onset of labor.
While maintained in a quiescent state during pregnancy, myometrium acquires a proactive state at term manifested by increased expression and function of contraction-associated proteins (CAPs) such as connexin 43 (Cx43), 1 cyclooxygenase 2 (Cox2), 2, 3 oxytocin receptor (OTR), 4 and prostaglandin receptors. 3, 5 The Cx43 mediates cell-to-cell connections between myometrial cells that are required for myometrium to conduct synchronized contraction during labor. The Cox2 catalyzes arachidonic acid to prostaglandin H 2 , which is the precursor of prostaglandin E 2 and F 2 that can bind prostaglandin receptors to stimulate myometrium contraction. The levels of OTR in myometrial cells also determine their responsiveness to oxytocin, a potent stimulator of myometrium contraction. Additionally, myometrial cells can secrete pro-inflammatory cytokines such as interleukin-1 beta (IL-1b) and IL-6 to attract leukocytes and amplify local myometrium inflammation reactions, 6 which in turn further enhance CAP gene expression. Elevated CAP expression activates the myometrium to be highly responsive to uterotonic stimulations and execute powerful synchronized contractions for delivery. 7 In addition to the general features discussed above, the human myometrium is unique because humans are bipedal, hence their uterus is more vertical than in quadruped species. During pregnancy, a contracted myometrium in the lower uterine segment (LUS) and a relaxed fundal (FUN) myometrium are needed to withstand the pressure on the cervix from the fetal head due to gravity. 7 At the onset of labor, this regional myometrium contractility will be compromised. Highly contractile FUN and relaxed LUS will permit descent of the fetus to cervix and expulsion of the fetus through the birth canal. These spatial mechanisms of the regionalized myometrium contractility had been proposed to be controlled by regionalized expression of CAPs in myometrium during pregnancy and labor. 7 In fact, regionalized myometrium phenotype had been reported previously including CAP genes such as Cx43, Cox2, OTR, and prostaglandin receptors. [8] [9] [10] [11] The question remains to be answered is how the regionalized CAP expression is regulated.
We have recently applied the RNA-seq technology to compare globally the transcriptome between FUN and LUS and identified that the homeobox protein A13 (HoxA13) gene is expressed at much higher levels in the LUS than the FUN myometrial cells. 12 The HoxA13 enhances myometrial cell contractility and cell-cell adhesion possibly through regulating the expression of prostacyclin synthase, periostin, and IL-1b. 12, 13 The HoxA13-induced IL-1b secretion in myometrial cells can not only stimulate IL-6 and IL-8 expressions to recruit leucocytes through a paracrine mechanism but also enhance the expression of CAPs including Cx43 and Cox2. These findings provide further evidence on the existence of regionalized myometrium phenotypes that mediate differential myometrium contractility in women. They also emphasize that HoxA13 plays a key role in controlling regionalized myometrium contractility.
The HoxA13 belongs to the HoxA family, which includes transcription factors sharing high homology in their DNA binding domains (homeodomain) but possessing variations in the amino terminus.
14 The amino terminus of HoxA members may interact with different cofactors, conferring different downstream signaling and cellular functions. The protein expression of HoxA members is spatially and temporally regulated during embryonic development, with the lower number gene members such as HoxA1 and HoxA2 being expressed more anteriorly and earlier than the higher number gene members such as HoxA10, HoxA11, and HoxA13, which are expressed more posteriorly along the vertebrate axial development.
14 Since humans do not have the HoxA12 gene and HoxA10 and HoxA11 were reported to be expressed in human uterus, 15 whether HoxA10 and HoxA11 play similar roles as HoxA13 to regulate CAP gene expression remain to be determined.
In this study, we designed experiments to investigate whether HoxA10 and HoxA11 are associated with regionalized myometrium phenotypes and whether these HoxA proteins also regulate CAP expressions thereby contributing to regionalized myometrium contractility.
Materials and Methods

Human Myometrium Biopsies
Ethics approval and informed consent were obtained for the collection of myometrium from women undergoing cesarean delivery (Conjoint Health Research Ethics Board, Office of Medical Bioethics, University of Calgary). 16 Paired FUN and LUS myometrial biopsies from term laboring (TL) and term nonlaboring (TNL) patients were collected (n ¼ 6 per group) for total RNA extraction and real-time polymerase chain reaction (PCR).
Real-Time PCR
Total RNA from either human myometrium biopsies or primary cultured myometrial cells were extracted by TRIZOL reagent (Invitrogen, Burlington, ON, Canada). RNA samples were treated with deoxyribonuclease and reversely transcribed by random hexamers and superscript II (Invitrogen). Real-time quantitative PCR (qPCR) was performed on the ABI PRISM 7900 HT system (Applied Biosystems, Burlington, ON, Canada) using the FastStart Universal SYBR Green Master mix (Roche, Laval, QU, Canada) following standard protocol as we reported. 17 Primer sets used include: IL-1b (forward:
, and HoxA13 (forward: 5 0 -CACGAACCCTTGGGTCTTC-3 0 ; reverse: 5 0 -TCTTTGGGGCAGTAC ATTTGG-3 0 ). All real-time qPCR assays were carried out in triplicates from 3 independent complementary DNA syntheses.
Primary Human Myometrial Cells
Myometrial biopsies were collected from the FUN and LUS of myometrium in pregnant women undergoing elective cesarean delivery before the onset of labor. 16, 18 Gestational age ranged from 37 weeks þ 2 days to 39 weeks þ 4 days. There were no clinical signs of labor, the cervix was firm and closed and the fetal membranes were intact. Indications for cesarean delivery included a previous cesarean delivery, breech presentation, or maternal request. Primary human myometrial smooth muscle cells were collected and cultured as described previously. 16, 19 Briefly, myometrial biopsies were collected into cold Hank's balanced salt solution (Life Technologies, Burlington, Ontario, Canada) containing antibiotic-antimycotic (Life Technologies) and chopped into small pieces. Tissue pieces were digested by collagenase XI and collagenase IA (SigmaAldrich, Oakville, Ontario, Canada). Myometrial cells were passed through a 70-mm cell sieve (Falcon, Fisher Scientific, Ottawa, Ontario, Canada) and cultured in PromoCell smooth muscle medium (PromoCell, Heidelberg, Germany). Myometrial cells were cultured within 3 to 5 passages before RNA extraction for real-time PCR and immunoblotting assays.
Human Myometrial Cell Lines
The human myometrial cell line (hTERT) was obtained from Dr Condon (University of Pittsburgh) and cultured in Dulbecco's modified Eagle (DMEM) medium. 19, 20 The cells were infected with lentivirus to stably express control or Flag-tagged HoxA10 or HoxA11. Briefly, lentiviral vectors encoding either control or HoxA10 or HoxA11 together with the ViraPower packaging mix (Invitrogen) were transfected into 293 T cells by Lipofectamine 3000 (Invitrogen) for 24 hours. Lentiviral particles were harvested by removing medium 48 hours after transfection and used to infect hTERT cells. The lentiviral vector contains Blasticidinresistant gene. In the presence of 10 mg/mL Blasticidin for 3 weeks, noninfected HMC cells were eliminated, and 3 hTERT-derived cell lines are generated: hTERT(CTL), hTERT(HoxA10), and hTERT(HoxA11). These cells were maintained in culture medium containing Blasticidin.
Immunoblotting
Whole cell lysates were extracted by a buffer containing 50 mM of Tris pH 8.0, 150 mM of NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and proteinase and phosphatase inhibitors (Roche). Immunoblotting assays followed the standard protocol as reported. 17 Antibodies used in immunoblotting include the anti-Cox2 antibody (Cayman Chemical, Michigan, USA; CAT# 160112), anti-Cx43 antibody (Millipore, Billerica, Massachusetts, USA; CAT# P17302), antib-actin antibody (Sigma-Aldrich, Oakville, Ontario, Canda; CAT# A5316), and anti-Flag antibody (Sigma-Aldrich; CAT# F3165). Experiments were repeated at least 3 times and only 1 set of the representative blots was shown.
Enzyme-Linked Immunosorbent Assay Assays
Human myometrial cells were seeded in flasks until they reached 80% confluency. Cells were washed twice with phosphate-buffered solution and replenished with serum-free DMEM media for 48 hours. The conditioned media were collected by centrifugation and used to measure IL-1b concentrations using the PicoKine™ enzyme-linked immunosorbent assay (ELISA) kit (Boster Bio, Pleasanton, California) following the manufacturer's protocol.
Statistical Analyses
Statistical analyses were carried out using GraphPad Prism (version 6, La Jolla, California) for 1-way analysis of variance followed by Tukey test with the level of significance set at P < .05 as * and P < .01 as **.
Results
HoxA10 and HoxA11 are Expressed at Higher Levels in FUN Than LUS
Using paired FUN and LUS myometrium biopsies, we applied real-time PCR to show that the mRNA copy numbers of HoxA10 were *500 to 20 000 in the FUN but only *50 to 500 in the LUS in 12 patients. Similarly, HoxA11 mRNA copy numbers were *200 to 1000 in the FUN, but *50 to 300 in the LUS ( Figure 1A) . No patients had higher HoxA10 and HoxA11 mRNA levels in the LUS than the FUN. When separating TL patients from TNL patients, HoxA10 and HoxA11 mRNAs remained significantly higher in the FUN than the LUS regardless of the TL or TNL status ( Figure 1B ). We were not able to measure HoxA10 and HoxA11 protein expressions due to limited tissue quantity to perform immunoblotting assays and lack of commercial antibody suitable for immunohistochemistry. However, we had also collected paired FUN and LUS primary myocytes from 3 TNL patients and showed that HoxA10 and HoxA11 mRNA levels were about 2-to 4-fold higher in the FUN than the LUS (Figure 2 ). These results were consistent to what we observed from patient biopsies. By contrast, HoxA13 mRNA levels were significantly lower in FUN (Figure 2 ). 12 We conclude from these results that HoxA10 and HoxA11 genes are highly expressed in the FUN but not in the LUS.
HoxA10 and HoxA11 Inhibit Cx43, Cox2, and IL-1b Expression in Myometrial Cells
To study the potential functions of HoxA10 and HoxA11 in myometrial cells, we have used a lentiviral approach to overexpress Flag-tagged HoxA10 and HoxA11 in the hTERT cell line. Although endogenous HoxA10 and HoxA11 were expressed at very low levels, enhanced HoxA10 and HoxA11 via lentiviral overexpression strongly suppressed IL-1b, IL-6, Cx43, and Cox2 mRNA levels ( Figure 3A) . At the protein level, both HoxA10 and HoxA11 strongly inhibited Cx43 protein expression ( Figure 3B ). Furthermore, our ELISA assays showed that the concentration of IL-1b was *7 pg/mL in the conditioned media from hTERT(CTL) cells, while we could not detect any IL-1b in the conditioned media collected from the hTERT(HoxA10) or hTERT(HoxA11) cells ( Figure 3C ). The Cox2 protein expression from the hTERT cells could not be detected by immunoblotting and thus, the suppression of Cox2 mRNA levels by HoxA10 and HoxA11 could not be validated at the protein level ( Figure 3B ). Together, these results indicated that HoxA10 and HoxA11 inhibit Cx43, Cox2, IL-1b, and IL-6 gene expression.
Since the hTERT cell line is a genetically engineered immortalized cell line thereby may not fully represent myometrial cells, we have also studied the correlation of CAP gene expression to HoxA10 and HoxA11 in primary cultured myocytes collected from the FUN and the LUS. The HoxA10 and HoxA11 are highly expressed in FUN myocytes ( Figure  2) , which also had significantly lower mRNA levels of IL-1b, IL-6, Cx43, and Cox2 ( Figure 4A) . Consistently, Cx43, Cox2, and IL-1b protein expressions were lower in the FUN than the LUS from all 3 patients (Figure 4B and C) . We conclude from these results that HoxA10 and HoxA11 inhibit CAP gene expression in human myometrial cells.
Discussion
In this study, we report that in contrast to the HoxA13, HoxA10 and HoxA11 genes are expressed at higher levels in the FUN compared to the LUS. We further showed that both HoxA10 and HoxA11 suppress Cx43, Cox2, and IL-1b protein expressions, opposite to that the actions mediated by HoxA13. These findings indicate that the differential expression patterns of HoxA protein family members create regionalized myometrium phenotypes that could possibly regulate regionalized myometrium contractility during pregnancy ( Figure 5 ). Figure 1 . Paired patient myometrium biopsies at term nonlaboring (TNL) or term laboring (TL) stage (n ¼ 6 patient/group) were collected to extract total RNA. HoxA10 and HoxA11 mRNA copy numbers were measured by real-time PCR using absolute quantification methods. Statistical analyses were performed by GraphPad Prism (version 6) for 1-way ANOVA followed by Tukey test with P < .05 as * and P < .01 as **. ANOVA indicates analysis of variance; HoxA, homeobox protein A; mRNA, messenger RNA; PCR, polymerase chain reaction. Figure 3 . hTERT(CTL), hTERT(HoxA10), and hTERT(HoxA11) cells were used to collect total RNA and whole cell lysates. A, HoxA10, HoxA11, IL-1b, IL-6, Cx43, and Cox2 mRNA levels were measured by real-time PCR. B, Flag-tagged HoxA10 and HoxA11, Cox2, and Cx43 protein levels were detected by immunoblotting assays. Immunoblotting results of Cox2 protein in hTERT cells treated with either vehicle or IL1b were used as controls. C, Conditioned media were collected from hTERT(CTL), hTERT(HoxA10), and hTERT(HoxA11) cells and used to measure secreted IL-1b levels by ELISA. Data were repeated in 3 independent experiments and shown as means + SEM with P < .01 as ** (1-way ANOVA followed by Tukey test). ANOVA indicates analysis of variance; Cox2, cyclooxygenase 2; Cx43, connexin 43; ELISA, enzyme-linked immunosorbent assay; HoxA, homeobox protein A; hTERT, human myometrial cell line; IL-1b, interleukin-1beta; IL-6, interleukin-6; mRNA, messenger RNA; PCR, polymerase chain reaction; SEM, standard error of the mean. Figure 4 . A, Paired primary myometrial cells (FUN vs LUS from 3 patients) were used to extract total RNA and used to perform real-time PCR to measure IL-1b, IL-6, Cx43, and Cox2 mRNA levels. B, Cx43 and Cox2 protein levels in FUN and LUS primary myocytes were measured by immunoblotting assays. C, Conditioned media were collected from primary myocytes and used to measure secreted IL-1b levels by ELISA. Data were repeated in 3 independent experiments and shown as means + SEM with P < .01 as ** (1-way ANOVA statistical followed by Tukey test). ANOVA indicates analysis of variance; Cox2, cyclooxygenase 2; Cx43, connexin 43; ELISA, enzyme-linked immunosorbent assay; FUN, fundus; IL-1b, interleukin-1beta; LUS, lower uterine segment; mRNA, messenger RNA; PCR, polymerase chain reaction; SEM, standard error of the mean.
The regionalized expression patterns of HoxA10, HoxA11, and HoxA13 in myometrium are consistent to the Hox code of the developing Mullerian system. 21 The lower numbers of HoxA members (eg, HoxA1 and HoxA2) are expressed in the anterior end, whereas the larger number of HoxA members (eg, HoxA10 and HoxA11) in the posterior end. The accuracy of the positions of HoxA members is needed to ensure the proper development of urogenital systems. 22 In adults, such spatial expression patterns of HoxA proteins remain despite overlaps to a certain extent, with HoxA10 and HoxA11 mainly expressed at the fundus of uterus, whereas HoxA13 is mainly expressed at the cervix end. 23, 24 Therefore, regionalized HoxA expressions in human uterus are largely controlled by the mechanisms for the development of human reproductive systems.
We report that HoxA10 and HoxA11 are highly expressed in the FUN and act to suppress the expression of several CAP genes including Cx43, Cox2, and IL-1b. In contrast, our previous studies showed that HoxA13 is highly expressed in the LUS and stimulates Cx43, Cox2, and IL-1b expression. 12, 13 The IL-1b secretion is also correlated with a greater leucocyte infiltration in the LUS. 13 Therefore, the differential expression patterns between HoxA10/HoxA11 and HoxA13 in the myometrium create regionalized expression patterns of CAPs that may lead to regionalized myometrium contractility. These findings provide an explanation of how the FUN is kept in a relaxed state, while the LUS in a contracted status during pregnancy to allow the fetus to be fully developed.
The regionalized expression of HoxA10 and HoxA11 in the myometrium remains the same during pregnancy and labor (Figure 1 ), suggesting that these proteins are important for the regionalized myometrium function during pregnancy but are not responsible for converting the contractility of FUN and LUS at the onset of labor. It should be noted that a much greater scale of elevation of CAP gene expressions occurs in the FUN at the onset of labor. These changes had been demonstrated to be triggered by the mechanisms such as a functional withdrawal of progesterone, 25 mechanical stretch approaching to the maximum by the growing fetus exert to the uterine wall, 26 and also recruitment and activation of leucocytes into myometrium. 27 Therefore, during pregnancy, high HoxA10 and HoxA11 and low HoxA13 expressions may maintain the basal contractility level of the FUN, which is lower than that of the LUS. At the onset of labor, a dramatic elevation of CAPs triggered by the progesterone signaling, mechanical stretch, and inflammation reactions within the FUN renders it highly contractile for labor. Why HoxA10/HoxA11 mediate different impacts on the expression of CAPs from HoxA13 remains to be determined. Although all 3 members are highly homologous in their homeodomains, HoxA13 has a characteristic region rich in alanine repeats flanked by proline, glycine, and serine in the amino terminus, 28 whereas HoxA10 and HoxA11 do not have this domain. These protein structure differences may result in different coregulator recruitment thereby target gene transcription rates. Similar observation had also been reported that HoxA3 induces, whereas HoxA5 suppresses endothelial cell migration and angiogenesis by modulating matrix metalloproteinase 4 (MMP4) gene expressions differently. 29, 30 An alternative explanation could be that HoxA10/HoxA11 do not necessarily play opposite roles to HoxA13 but may function as dominant negative regulators for HoxA13 using their homeodomains to compete with HoxA13 on target cis elements.
In summary, we report regionalized HoxA10 and HoxA11 expressions between the FUN and LUS. The HoxA10 and HoxA11 suppress several CAP gene expressions, suggesting that they may control regionalized myometrium contractility during pregnancy. 
